These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 17473179
1. Drug safety and drug efficacy: two sides of the same coin. Young RC, Friedman MA, Schilsky RL, Sigal EV. Clin Cancer Res; 2007 May 01; 13(9):2533-4. PubMed ID: 17473179 [No Abstract] [Full Text] [Related]
2. Bolstering the FDA's drug-safety authority. Schultz WB. N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024 [No Abstract] [Full Text] [Related]
3. New law gives FDA more influence to monitor drug safety. Wadman M. Nat Med; 2007 Nov 29; 13(11):1269. PubMed ID: 17987008 [No Abstract] [Full Text] [Related]
4. The marketplace can't give us the drug safety data we need. Avorn J. MedGenMed; 2007 Feb 09; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
5. Drug-review deadlines and safety problems. Nardinelli C, Lanthier M, Temple R. N Engl J Med; 2008 Jul 03; 359(1):95-6; author reply 96-8. PubMed ID: 18596282 [No Abstract] [Full Text] [Related]
6. A regulatory perspective on issues and approaches in characterizing human metabolites. Davis-Bruno KL, Atrakchi A. Chem Res Toxicol; 2006 Dec 03; 19(12):1561-3. PubMed ID: 17173368 [Abstract] [Full Text] [Related]
7. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned. Mathis LL, Iyasu S. Clin Pharmacol Ther; 2007 Aug 03; 82(2):133-4. PubMed ID: 17632537 [Abstract] [Full Text] [Related]
8. Is having more preapproval data the best way to assure drug safety? Garber AM. Health Aff (Millwood); 2008 Aug 03; 27(5):w371-3. PubMed ID: 18682442 [Abstract] [Full Text] [Related]
9. The process of evaluating and regulating a new drug: phases of a drug study. Cowan CC. AANA J; 2002 Oct 03; 70(5):385-90. PubMed ID: 12425128 [Abstract] [Full Text] [Related]
10. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty. Goldman SA. Food Drug Law J; 2007 Oct 03; 62(3):513-28. PubMed ID: 17915393 [No Abstract] [Full Text] [Related]
11. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F. Eur Heart J; 2007 Aug 03; 28(15):1904-9. PubMed ID: 17615083 [Abstract] [Full Text] [Related]
12. Meeting REMS head on. Walker S. Health Manag Technol; 2011 Jul 03; 32(7):34. PubMed ID: 21863707 [No Abstract] [Full Text] [Related]
13. Reforms on drug safety. Nature; 2006 Sep 28; 443(7110):372. PubMed ID: 17006474 [No Abstract] [Full Text] [Related]
14. Drug safety: a contrarian's point of view. Cobert B. Food Drug Law J; 2007 Sep 28; 62(3):501-12. PubMed ID: 17915392 [No Abstract] [Full Text] [Related]
15. What has been happening with over-the-counter drug regulation. Stringer S. Food Drug Law J; 1998 Sep 28; 53(4):633-41. PubMed ID: 10557581 [No Abstract] [Full Text] [Related]
16. The drug safety review process. Somberg J. Am J Ther; 2007 Sep 28; 14(2):119. PubMed ID: 17414577 [No Abstract] [Full Text] [Related]
17. Law gives FDA new enforcement clout. Traynor K. Am J Health Syst Pharm; 2007 Nov 15; 64(22):2314-5. PubMed ID: 17989436 [No Abstract] [Full Text] [Related]
18. Report hits FDA to revamp safety oversight. Finkelstein JB. J Natl Cancer Inst; 2006 Jul 05; 98(13):884-5. PubMed ID: 16818849 [No Abstract] [Full Text] [Related]
19. Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project. Bennett CL, Tigue CC, Angelotta C, McKoy JM, Edwards BJ. Semin Thromb Hemost; 2007 Jun 05; 33(4):365-72. PubMed ID: 17525894 [Abstract] [Full Text] [Related]
20. How is a food product recalled? Cunningham E. J Am Diet Assoc; 2009 Aug 05; 109(8):1488. PubMed ID: 19631055 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]